Publications scientifiques et présentations

Ces publications scientifiques et présentations sont proposées à des fins de formation uniquement. Elles peuvent mentionner ou discuter des produits de DBV Technologies en cours de développement, et qui ne sont approuvés pour commercialisation par aucune autorité règlementaire ou de santé dans aucun pays du monde.

Publications importantes

Greenhawt M, Albright D, Anvari S, et al.
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE
J Allergy Clin Immunol Pract. Published online February 14, 2025. PMID: 39956162 | doi:10.1016/j.jaip.2025.02.004
Petroni D, Bégin P, Bird JA, et al.
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy: A Randomized Clinical Trial
JAMA Pediatr. 2024; 178(4): 345–353. PMID: 38407859 | doi: 10.1001/jamapediatrics.2023.6630
Dupont C, Burks AW, Fleischer DM, Bee KJ, Chainani S, Sampson HA
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
Expert Rev Clin Immunol. Published online February 14, 2024. PMID: 38323337 | doi:10.1080/1744666X.2024.2315221
Stukus DR, Gupta R, Mack D, et al.
Epicutaneous immunotherapy with Viaskin™ Peanut in toddlers: a plain language summary
Immunotherapy. 2024;16(1):5-13. PMID: 38112107 | doi:10.2217/imt-2023-0201
Hervé PL, Dioszeghy V, Matthews K, Bee KJ, Campbell DE, Sampson HA
Recent advances in epicutaneous immunotherapy and potential applications in food allergy
Front Allergy. 2023;4:1290003. PMID: 37965375 | doi:10.3389/falgy.2023.1290003
Matthew Greenhawt, M.D., Sayantani B. Sindher, M.D., Julie Wang, M.D., et al.
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
New England Journal of Medicine 2023; 388:1814-1815 | doi:10.1056/NEJMe2301157
Pongracic JA, Gagnon R, et al.
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
J Allergy Clin Immunol Pract. 2021. Nov 27;S2213-2198(21)01295-2. | doi:10.1016/j.jaip.2021.11.017
Bégin P, Bird JA, et al.
Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy
Allergy. 2021. Dec;76(12):3835-3838. | doi: 10.1111/all.15083.
Remington BC, Koppelman SJ, et al.
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Allergy. 2021. Oct;76(10):3223-3226. | doi: 10.1111/all.14973.
Brown-Whitehorn TF, de Blay F, et al.
Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. | doi: 10.1016/j.jaip.2020.08.017.
DunnGalvin A, Fleischer DM, et al.
Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. | doi: 10.1016/j.jaip.2020.08.015.
Remington BC, Campbell DE, et al.
Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results
Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. | doi: 10.1016/j.anai.2020.11.015.
Fleischer DM, Shreffler WG, et al.
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
The Journal of Allergy and Clinical Immunology. 2020. | doi:10.1016/j.jaci.2020.06.028.
Greenhawt M, Kim EH, et al.
Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years
The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. PMID: 32502548. | doi:10.1016/j.jaip.2020.05.030.
Fleischer DM, Chinthrajah S, et al.
An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial
Allergy & Asthma Proceedings. 2020;41:1-10. PMID: 32539908. | doi:10.2500/aap.2020.41.200047.
Fleischer DM, Spergel JM, et al.
Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy
Allergy & Asthma Proceedings. 2020;41:278-284. PMID: 32517847. | doi:10.2500/aap.2020.41.200045
Fleischer DM, Greenhawt M, et al.
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. PMID: 30794314. | doi:10.1001/jama.2019.1113.
Sampson HA, Shreffler WG, et al.
Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity
A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. PMID: 29136445. | doi:10.1001/jama.2017.16591.
Get the Quarterly Newsletter from DBV Technologies Medical Affairs & Clinical Development
S’inscrire

Présentations Récentes

Ces résumés ont été approuvés pour présentation à un congrès médical et n’ont pas été soumis à une revue complète par des pairs.

Oral abstract for American Academy of Allergy, Asthma & Immunology (AAAAI)/ World Allergy Organization (WAO) 2025 Joint Congress, February 28-March 3, 2025:

Oral Abstract:

  • Long-Term Efficacy Results of Epicutaneous Immunotherapy With VIASKIN® Peanut Patch in Peanut-Allergic Children. Aged 4-11 Years in the Phase 3 PEOPLE Study: San Diego, CA – Fleischer DM, Ford LS, Oriel RC, et al. [Abstract]

Eastern Food Allergy & Comorbidity Conference, January 9-12, 2025:

Poster Presentations:

  • EPOPEX (EPITOPE Open-label Extension), Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers After 3 Years of Treatment: Palm Beach, FL – Greenhawt M, Wang J, Du Toit G, et al. [Poster]
  • VP250 Average Daily Wear Time: Impact on Efficacy and Safety in the Phase 3 EPITOPE Study: Palm Beach, FL – Kim EH, Fleischer DM, Leonard S, et al. [Poster]
  • Changes in Biomarkers During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers: Palm Beach, FL – Kim EH, Lieberman J, Schneider L, et al. [Poster]

European Academy of Allergy and Clinical Immunology (EAACI) 2024 Annual Meeting, May 31-June 3, 2024:

Presentation:

  • Reactions due to Accidental Peanut Consumption During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers: Valencia, Spain – Arends N, Vogelberg C, Turner PJ, et al. [Poster]

American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting, February 23-26, 2024:

Poster Presentation:

  • Long-Term Safety Results of Epicutaneous Immunotherapy (EPIT) With Viaskin Peanut in Peanut-Allergic Children Aged 4 Through 11 Years in the Phase 3 PEOPLE Study: Washington, DC – Fleischer DM, Ford LS, Sussman G, et al. [Poster]
Retour en haut